ArticleInternational journal of endocrinology2026
Percutaneous Ethanol Ablation of Parathyroid Adenoma and Parathyroidectomy Are Comparable.
Article in International journal of endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Percutaneous Ethanol Ablation of Parathyroid Adenoma and Parathyroidectomy Are Comparable.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: To compare ethanol injection of parathyroid adenoma with surgical parathyroidectomy (PTX). Methods: A prospective, partially randomized preference clinical trial of two groups assigned to surgical PTX (20 patients) or ethanol injection (PEA) (10 patients). The inequality was due to patient preferences and limitations caused by the coronavirus pandemic. Results: Both PEA and PTX resulted in 80% or more of patients having normalized calcium levels after one month. These were sustained through 6 months. A significant proportion of patients after both PEA and PTX had normalized PTH levels after one month (55% and 70%, respectively), which remained unchanged at the 3- and 6-month measurements. After 12 months, calcium and parathyroid hormone levels were lower in the PTX group, while phosphorus levels were higher; however, the differences were not statistically significant. Complications were more common in the PTX group, although the difference was not statistically significant. Conclusion: Overall, PEA and PTX have similar outcomes. Although not statistically significant, the PEA of parathyroid adenoma causes a less pronounced effect on calcium and parathyroid hormone levels and has fewer side effects.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.